Regulus Therapeutics Inc. (RGLS) News
Filter RGLS News Items
RGLS News Results
Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
---|---|---|---|---|---|---|---|---|---|
Loading, please wait... |
Latest RGLS News From Around the Web
Below are the latest news stories about REGULUS THERAPEUTICS INC that investors may wish to consider to help them evaluate RGLS as an investment opportunity.
Regulus Therapeutics to Present at the 6th Annual Evercore ISI HealthCONx ConferenceRegulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the "Company" or "Regulus"), today announced that CEO Jay Hagan will be participating in a fireside chat at the 6th Annual Evercore ISI HealthCONx Conference on Wednesday November 29, at 10:25 a.m. ET. |
Regulus Therapeutics Reports Third Quarter 2023 Financial Results and Recent UpdatesRegulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the "Company" or "Regulus"), today reported financial results and provided a corporate update for the third quarter ended September 30, 2023. |
Regulus Therapeutics Announces First Patient Dosed in Third Cohort of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the "Company" or "Regulus"), today announced the dosing of the first patient in the third cohort of the Phase 1b MAD study of RGSL8429 for the treatment of ADPKD. |
Regulus Therapeutics Advances to Cohort 3 of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the "Company" or "Regulus"), today announced, after review of all available safety data, that it will advance to the third cohort of patients in the Phase 1b MAD study of RGSL8429 for the treatment of ADPKD. Patients in the third cohort will receive 3 mg/kg of RGLS8429 or placebo every other week for three months. |
Regulus Therapeutics Announces Positive Topline Data from the First Cohort of Patients in its Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the "Company" or "Regulus"), today announced positive topline results from the first cohort of patients in its Phase 1b MAD study of RGLS8429 for the treatment of ADPKD. |
Regulus Therapeutics Announces Completion of Enrollment in Second Cohort of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD)Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the "Company" or "Regulus"), today announced it has completed enrollment in the second cohort of patients in the ongoing Phase 1b MAD study of RGSL8429 for the treatment of ADPKD. |
Regulus Therapeutics Announces Participation at Two Healthcare Investment ConferencesRegulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the "Company" or "Regulus"), today announced that the Company will host investor meetings at the Wells Fargo Healthcare Conference, and present and host meetings at the H.C. Wainwright 25th Annual Global Investor Conference. |
Regulus Therapeutics (RGLS): An Attractive Valuation or a Potential Value Trap?Unveiling the Underlying Risks and Rewards of Investing in Regulus Therapeutics |
Regulus Therapeutics Inc's Uncertain Future: Understanding the Barriers to OutperformanceAn In-depth Analysis of Regulus Therapeutics Inc's GF Score |
Regulus Therapeutics to Host Virtual Investor Event on September 6, 2023Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the "Company" or "Regulus"), today announced that it will host a virtual investor event on Wednesday, September 6, 2023, focused on its lead program, RGLS8429, a novel therapy in clinical development for the treatment of autosomal dominant polycystic kidney disease (ADPKD). |